TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01185002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PillCam® COLON 2 procedure using MgC boosts
Description: Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take MgC boosts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PillCam® COLON 2 procedure using Suprep boosts
Description: Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take Suprep boosts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PillCam® COLON 2 procedure using reduced dose of Suprep boosts
Description: Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take reduced dose of Suprep boosts
Study: NCT04020978

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Parametric PET/CT
Description: Each patient will undergo a dynamic F18-FDG PET/CT scan at baseline and 2-week post therapy.
Study: NCT02951052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir (CAB) tablet
Description: It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) tablet
Description: It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir - Injectable Suspension (CAB LA)
Description: It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine - Injectable Suspension (RPV LA)
Description: It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 NRTIs plus an INI, NNRTI, or PI
Description: Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus:~* INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen)~* NNRTI (either the initial or second cART regimen)~* Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)
Study: NCT04040088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-DOTATATE
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-DOTATATE
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT04421963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg olaparib (2×150 mg tablets) twice daily
Study: NCT03959527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoliflodacin
Description: Dose: 3g, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: Dose: 500mg, Intra-Muscular (IM) administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: Dose: 1g, oral administration
Study: NCT06433843

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dialectical behavioral therapy for the treatment of posttraumatic stress disorder (DBT-PTSD)
Description: 12 weeks inpatient disorder specific psychotherapy
Study: NCT04407143

Intervention type: DIAGNOSTIC_TEST
Intervention: IgG test
Description: IgG+ blood test by ELISA method.
Study: NCT04716621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early intervention
Description: The Pain Management Support System for Primary Care (PMSS-PC) generated best practice alerts and gave clinicians access to a pain assessment template, measures of psychological distress and substance use, guidelines for drug and non-drug therapies, and facilitated referrals. At implementation, clinicians at the practices were offered in-person and virtual education through six webinars on best practices for pain.

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed intervention
Description: Delayed wait-list control group. The second arm involved three additional sites receiving the PMSS-PC intervention 6 months after the first arm. Initial outcomes from the PMSS-PC Experimental Intervention arm were compared to those of this Wait-list Control arm.
Study: NCT04404348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Exercises used will be: Mind Bender, Divided Attention, Freeze Frame, Mixed Signals, Target Tracker, To Do List.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Games are drawn from the set of research control games provided by Posit Science-Brain HQ.
Study: NCT01135524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
Study: NCT03306095

Intervention type: OTHER
Intervention: Early refeeding group
Description: Food Intake by patient with in 4 hours i.e \<4 hours after the EVL procedure

Intervention type: OTHER
Intervention: Early refeeding group
Description: Food Intake by patient with in 4 hours i.e \<4 hours after the EVL procedure

Intervention type: OTHER
Intervention: Delayed refeeding group
Description: Food Intake by patient after 4 hours i.e \> 4 hours after the EVL procedure

Intervention type: OTHER
Intervention: Delayed refeeding group
Description: Food Intake by patient after 4 hours i.e \> 4 hours after the EVL procedure
Study: NCT03387969

Intervention type: PROCEDURE
Intervention: CSF sample
Description: for all patient CSF sample obtained for analysis , culture sensitvity and CSF-CRP.~also blood samples will be collected and analyzed for serum procalcitonin
Study: NCT04371055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7-day Holter ECG
Description: 7-day Holter ECG at baseline and after 3 and 12 months and then annually until the end of the study or the first (in patients with low risk of atrial fibrillation)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor
Description: Continuous rhythm monitoring using an implantable cardiac monitor
Study: NCT02790918

Intervention type: OTHER
Intervention: 6MWT
Description: Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory. Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.

Intervention type: OTHER
Intervention: 6MWT
Description: Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory. Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging (CMRI)
Description: MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging (CMRI)
Description: MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
Study: NCT00397189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Circadin
Description: Prolonged release melatonin 2 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo circadin
Description: placebo circadin tablets
Study: NCT00925808

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Survey tools and VTE Symptom Follow-up Questionnaire
Study: NCT03238794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-En-Y Gastric Bypass
Description: Food will be consumed as directed by their doctor as standard of care. A food log will be completed the week before visits 3 and 5.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-calorie Diet
Description: Food will be consumed as Week one will be liquid 400 to 500 kcal/day, weeks 2,3, and 4 will consist of 500-600 kcal/day of pureed food, weeks 5-8 will consist of 600-800 kcal/day of mechanical-soft food, weeks 9-12 will consist of 800 to 1000 kcal/day of soft foods, and the remainder of the study participants will be given 1000 to 1200 kcal/day of regular food.
Study: NCT02027077

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: No prescribed intervention/ Participants asked to follow normal initiatives to engage in physical activity a healthful diet behaviors for the duration of the intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counselling
Description: Participants will follow a prescribed behavioral intervention program seeking small changes in both physical activity and diet for the duration of the intervention.
Study: NCT04430088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: IV infusion of 1000 mg of VVZ-149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of 0 mg of VVZ-149
Study: NCT02904083

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self assessment of adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self assessment of adherence
Study: NCT04371055

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Usual care according to current guidelines (in patients with low and high risk of atrial fibrillation)
Study: NCT00807612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 at 12 mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 12 mg/kg IV monotherapy for up to 24 months from study day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 at 18mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on Day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 18 mg/kg IV monotherapy for up to 24 months from day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 6) IV infusion over 30 (± 10) minutes according to institutional guidelines Day 1 of Cycle 1 to 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 6) IV infusion over 30 (± 10) minutes according to institutional guidelines Day 1 of Cycle 1 to 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 6) IV infusion over 30 (± 10) minutes according to institutional guidelines Day 1 of Cycle 1 to 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 IV in combination with chemotherapy on day 1 of every 3 week cycle for 4 to 6 cycles, followed by AMG 479 IV monotherapy for up to 24 months from study day 1. The AMG 479 dose to be used will be the final AMG 479 dose explored from Part 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel at 200 mg/m2 IV infusion over 3 hours (± 30 minutes) according to institutional guidelines Day 1 of Cycle 1 to 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel at 200 mg/m2 IV infusion over 3 hours (± 30 minutes) according to institutional guidelines Day 1 of Cycle 1 to 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel at 200 mg/m2 IV infusion over 3 hours (± 30 minutes) according to institutional guidelines Day 1 of Cycle 1 to 6
Study: NCT00766623

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high fat meal
Description: milkshake containing 95g fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high fat meal
Description: milkshake containing 95g fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high fat meal
Description: milkshake containing 95g fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control meal
Description: milkshake comparable with a normal breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control meal
Description: milkshake comparable with a normal breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control meal
Description: milkshake comparable with a normal breakfast
Study: NCT00056303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up
Description: Attachment and Biobehavioral Catch-up is a 10 session in-home intervention that targets synchrony, nurturance, and calming parental behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Education for Families
Description: Developmental Education for Families is a 10-session in home intervention that targets children's cognitive development.
Study: NCT02913781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: polar body removal using zona drilling by laser then suction by injecting pipette
Description: zona drilling with laser followed by polar body removal then ICSI procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Classic ICSI
Description: Classic ICSI case was done be injecting sperm inside Oocyte while polar body is already existed at 6 or 12 O'clock position.
Study: NCT00608218

Intervention type: DRUG
Intervention: Ciclesonide
Description: This is an observational study. Therefore, the physician decides about dosage according to individual needs.
Study: NCT02233621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]FES (16α-[18F]Fluoro-17β-estradiol)
Description: PET with \[18F\]FES before coelioscopy
Study: NCT03060291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCU-Online, web/ mobile only
Description: Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FCU-Online, web/ mobile + coach
Description: Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior. Participants will also have access to a family coach who will motivate parents to enhance parenting skills and provide support while they are learning to use these skills.
Study: NCT02714036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibudilast
Description: Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast
Description: Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
Study: NCT02855567

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture needles
Description: Acupuncture needles (29 and 30 gauge) used to perform the acupuncture

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture needles
Description: Acupuncture needles (29 and 30 gauge) used to perform the acupuncture
Study: NCT03864003

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Workers and Teleaudiology as a Culturally-Relevant Approach to Improving Access to Hearing Health Care
Description: In this project, remote hearing aid fittings will be delivered by an audiologist with patient-site support from a local facilitator for a cohort of older adults (\>50 years) from a rural area that has been identified as under-resourced for hearing health care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Workers and Teleaudiology as a Culturally-Relevant Approach to Improving Access to Hearing Health Care
Description: In this project, remote hearing aid fittings will be delivered by an audiologist with patient-site support from a local facilitator for a cohort of older adults (\>50 years) from a rural area that has been identified as under-resourced for hearing health care.
Study: NCT03925181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling Group
Description: All sessions will be based off of SAMHSA's recovery curriculum but tailored to the participants recovering from the ICU and their caregivers. Throughout the 6-weeks, the sessions will be holistic, strengths-based, hopeful, respectful, relational, and subjective, while emphasizing social relationships, social contexts, and meaning and purpose.
Study: NCT02372994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loop
Description: Loop is a secure online communication system centered on the patient that assembles the patient's actual healthcare team for ongoing collaborative care. The patient and caregiver are integral members of the team. Loop is cross-organizational, cross-setting and interprofessional. It is for ongoing, interactive, contextual, team-based communication. Loop is explicitly for asynchronous communication, not instant messaging. The stream of messages is stored and can be sorted for ease of viewing. The tool was developed with user-centred design and requires no prior training.
Study: NCT01018914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic
Description: oral
Study: NCT01817166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Imaging
Description: All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lumbar puncture
Description: A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Urine samples
Description: Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urine samples
Description: Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.